Sector News

J&J walks away from Actelion deal talks

December 15, 2016
Life sciences

Johnson & Johnson has bowed out of a potential merger with Actelion, opening up the field for an unconfirmed contender widely believed to be French drugmaker Sanofi.

The US healthcare giant confirmed that it has withdrawn from discussions over a potential takeover, which would have bolstered its lung disease offering with Actelion’s pulmonary arterial hypertension portfolio.

The firm did not give a detailed reason for the move, saying only that it had not been able to reach an agreement that would create adequate value for its shareholders.

But Reuters has cited people close to the situation saying that the Swiss biotech told J&J that it could attract an offer significantly above the approximate 250 Swiss francs per share (reportedly around $27 billion) it had laid on the table, and that there were issues over the deal structure.

Actelion confirmed that it is “engaged in discussions with another party regarding a possible strategic transaction,” but stressed that “there can be no certainty at this point that any transaction will result”.

The Wall Street Journal has reported that this party is Sanofi, also citing people close to the situation.

By Selina McKee

Source: Pharma Times

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach